Kiwi Wealth Investments Limited Partnership acquired a new position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 2,354 shares of the biopharmaceutical company’s stock, valued at approximately $879,000.
Several other large investors also recently bought and sold shares of REGN. Capital International Investors purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $703,075,000. FMR LLC lifted its holdings in Regeneron Pharmaceuticals by 17.0% during the 3rd quarter. FMR LLC now owns 5,016,501 shares of the biopharmaceutical company’s stock worth $2,026,867,000 after buying an additional 728,104 shares in the last quarter. Capital World Investors lifted its holdings in Regeneron Pharmaceuticals by 5.3% during the 3rd quarter. Capital World Investors now owns 6,384,323 shares of the biopharmaceutical company’s stock worth $2,579,522,000 after buying an additional 322,051 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in Regeneron Pharmaceuticals by 35.8% during the 3rd quarter. Alliancebernstein L.P. now owns 1,023,594 shares of the biopharmaceutical company’s stock worth $413,573,000 after buying an additional 269,696 shares in the last quarter. Finally, Morgan Stanley lifted its holdings in Regeneron Pharmaceuticals by 70.6% during the 3rd quarter. Morgan Stanley now owns 464,603 shares of the biopharmaceutical company’s stock worth $187,719,000 after buying an additional 192,236 shares in the last quarter. 66.87% of the stock is owned by hedge funds and other institutional investors.
In related news, VP Christopher R. Fenimore sold 1,848 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, December 20th. The shares were sold at an average price of $358.97, for a total transaction of $663,376.56. Following the sale, the vice president now directly owns 9,871 shares in the company, valued at approximately $3,543,392.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Joseph L. Goldstein sold 1,791 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, January 10th. The stock was sold at an average price of $410.00, for a total transaction of $734,310.00. Following the sale, the director now owns 14,114 shares in the company, valued at $5,786,740. The disclosure for this sale can be found here. Insiders have sold a total of 134,754 shares of company stock worth $55,439,356 over the last quarter. 12.42% of the stock is owned by company insiders.
Shares of REGN opened at $407.50 on Friday. Regeneron Pharmaceuticals Inc has a twelve month low of $281.89 and a twelve month high of $442.00. The firm has a market capitalization of $44.53 billion, a PE ratio of 20.58, a PEG ratio of 1.68 and a beta of 1.20. The company has a current ratio of 4.47, a quick ratio of 3.67 and a debt-to-equity ratio of 0.08.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Wednesday, February 6th. The biopharmaceutical company reported $6.84 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $5.10 by $1.74. Regeneron Pharmaceuticals had a net margin of 36.43% and a return on equity of 29.77%. The firm had revenue of $1.93 billion for the quarter, compared to analyst estimates of $1.73 billion. During the same period last year, the business earned $5.23 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 21.9% compared to the same quarter last year. Equities analysts expect that Regeneron Pharmaceuticals Inc will post 19.92 EPS for the current year.
REGN has been the topic of a number of research reports. BidaskClub lowered shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, November 16th. Oppenheimer set a $440.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, December 2nd. Leerink Swann set a $483.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, December 7th. They noted that the move was a valuation call. Goldman Sachs Group upgraded shares of Regeneron Pharmaceuticals from a “neutral” rating to a “conviction-buy” rating in a report on Thursday, December 13th. Finally, ValuEngine upgraded shares of Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 15th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Regeneron Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $413.76.
COPYRIGHT VIOLATION WARNING: This story was first published by Highlight Press and is the property of of Highlight Press. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://highlightpress.com/2019/03/15/kiwi-wealth-investments-limited-partnership-purchases-shares-of-2354-regeneron-pharmaceuticals-inc-regn.html.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.